Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of Rectal Cancer Response to Chemoradiation
NCT00335816Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2008
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of fluorouracil, oxaliplatin and folinic acid in rectal cancer (4 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Rate of pathologic complete response, Effect of different chemoradiation-to-surgery intervals on rate of pathologic complete response and surgical difficulty and 1 more. Started Aug 2008; status: active, not recruiting.
02
Drugs
fluorouraciloxaliplatinfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00335816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335816.